Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Does neoadjuvant chemotherapy provide a survival benefit in maxillofacial osteosarcoma: A systematic review and pooled analysis.

Tytuł:
Does neoadjuvant chemotherapy provide a survival benefit in maxillofacial osteosarcoma: A systematic review and pooled analysis.
Autorzy:
Khadembaschi D; School of Medicine, University of Queensland, Herston, Australia. Electronic address: .
Jafri M; Department of Oncology, University Hospital Birmingham, United Kingdom.
Praveen P; Department of Maxillofacial Surgery, University Hospital Birmingham, United Kingdom.
Parmar S; Department of Maxillofacial Surgery, University Hospital Birmingham, United Kingdom.
Breik O; Department of Maxillofacial Surgery, Royal Brisbane and Women's Hospital, Queensland, Australia.
Źródło:
Oral oncology [Oral Oncol] 2022 Dec; Vol. 135, pp. 106133. Date of Electronic Publication: 2022 Oct 10.
Typ publikacji:
Systematic Review; Journal Article; Review
Język:
English
Imprint Name(s):
Publication: Amsterdam : Elsevier
Original Publication: Oxford ; New York : Pergamon, c1997-
MeSH Terms:
Osteosarcoma*/pathology
Head and Neck Neoplasms*/drug therapy
Bone Neoplasms*/pathology
Humans ; Neoadjuvant Therapy ; Chemotherapy, Adjuvant
Contributed Indexing:
Keywords: Chemotherapy; Head and Neck Neoplasms; Neoadjuvant therapy; Osteosarcoma; Survival
Entry Date(s):
Date Created: 20221013 Date Completed: 20221128 Latest Revision: 20221208
Update Code:
20240104
DOI:
10.1016/j.oraloncology.2022.106133
PMID:
36228524
Czasopismo naukowe
Maxillofacial osteosarcoma (MFOS) is a rare disease that presents and behaves differently to the more commonly seen osteosarcoma (OS) of long bones. Neoadjuvant chemotherapy (neoCTx) has been shown to increase survival in OS of long bones, however it is contentious whether it has the same benefit when treating MFOS. The aim of this review was to determine whether neoCTx has a survival benefit for MFOS. Pubmed/Medline, EMBASE and CINAHL databases were searched. Of the 264 studies identified 18 were included reporting on the effect of neoCTx on survival. Individual data of 222 patients was pooled, and survival was estimated using Kaplan-Meier method and variables were assessed using Cox regression. NeoCTx had no significant effect on disease specific survival (p = 0.28). Margin status, age and grade of tumour had a significant effect on survival. This study did not find a consistent survival benefit for neoCTx over surgery as the primary treatment modality in the management of osteosarcomas of the head and neck.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies